ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
Ovarian Neoplasms
DRUG: Sagopilone (ZK 219477) + carboplatin
Response to treatment with ZK-Epo after 6 cycles, After 6 cycles
Safety and tolerability of ZK-Epo given with carboplatin, Sept. 2008
This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is sponsoring this trial.